No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
180 |
4. Check minimum number of eventsNone |
180 |
5. Include endpointsNone |
180 |
6. Filter based on genotype QC (FinnGen only) |
180 |
Control definitions (FinnGen only)
- Control exclude
- F5_DEMENTIA, G6_ALZHEIMER, G6_AD_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Frontotemporal dementia
based on the number of shared cases.
Similar with more cases:
- Frontotemporal dementia, wide, incl. Pick's disease
- Circumscribed brain atrophy
- Dementia in other diseases classified elsewhere
- Degenerative diseases of the nervous system
- Other degenerative diseases of the nervous system
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2112 | 1189 | 909 |
| Only index persons | 1877 | 1084 | 793 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 71.43 | 72.17 | 70.41 |
| Only index persons | 71.37 | 72.13 | 70.33 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 180 | 79 | 101 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.04 |
| Median age at first event (years) | 69.65 | 70.57 | 68.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 148
- Matched controls
- 1480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F02.09*G31.0
ICD-10 Finland
Dementia in Pick's disease without information on additional symptoms
+∞
141.1
112
*
G31.0
ICD-10 Finland
Circumscribed brain atrophy
619.6
74.8
68
*
F03
ICD-10 Finland
Unspecified dementia
94.0
43.0
46
7
N05AX08
ATC
risperidone; systemic
28.2
40.3
56
31
N05AH04
ATC
quetiapine; oral
17.0
39.8
69
72
N05AH03
ATC
olanzapine; systemic
28.8
28.8
39
18
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
12.3
27.3
53
64
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
10.9
27.2
57
80
N03AG01
ATC
valproic acid; systemic, rectal
17.3
26.5
43
34
F02.09
ICD-10 Finland
Dementia in Pick's disease without information on additional symptoms
+∞
25.8
24
*
TAB00
NOMESCO Finland
Lumbar puncture
17.8
25.1
40
30
N06DA02
ATC
donepezil; oral
283.5
24.4
24
*
P70
ICPC
Dementia
148.9
24.4
25
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
15.1
22.4
38
33
N06DX01
ATC
memantine; oral
255.8
22.2
22
*
XA800
NOMESCO Finland
Neuropsychological investigation
21.1
21.7
32
19
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
14.9
20.6
35
30
N05BA06
ATC
lorazepam; systemic, sublingual
18.2
20.5
32
22
F0203, G310
ICD-10 Finland
NA
+∞
18.1
17
*
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
101.6
16.9
18
*
F06.7
ICD-10 Finland
Mild cognitive disorder
24.4
16.6
23
11
P20
ICPC
Memory disturbance
5.9
15.9
50
118
A28
ICPC
Limited function/disability NOS
5.1
15.6
59
171
F0204, G310
ICD-10 Finland
NA
+∞
14.8
14
*
F0200, G310
ICD-10 Finland
NA
+∞
13.7
13
*
N06DA03
ATC
rivastigmine; oral, transdermal
153.2
13.7
14
*
N06AX11
ATC
mirtazapine; oral
4.0
13.0
68
261
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
+∞
12.7
12
*
IGY02
NOMESCO Finland
Psychiatric monitoring contact
51.1
12.1
14
*
G30.9
ICD-10 Finland
Alzheimer disease, unspecified
+∞
11.6
11
*
N05BA04
ATC
oxazepam; oral
3.8
11.0
56
204
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
8.9
10.9
23
30
IAB14
NOMESCO Finland
Geriatric psychiatry consultation
117.8
10.6
11
*
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
25.5
10.4
14
6
N06AB10
ATC
escitalopram; oral
4.4
10.0
39
111
IGY99
NOMESCO Finland
Other psychiatric treatment contact
58.8
9.8
11
*
RT250
NOMESCO Finland
NA
106.3
9.5
10
*
IBZ07
NOMESCO Finland
Neurological assessment in psychiatry
+∞
9.5
9
*
F0202, G310
ICD-10 Finland
NA
+∞
9.5
9
*
N06AX16
ATC
venlafaxine; oral
4.8
9.3
32
80
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
39.2
9.1
11
*
R41.0
ICD-10 Finland
Disorientation, unspecified
9.6
9.1
18
21
G30.1
ICD-10 Finland
Alzheimer disease with late onset
25.9
9.1
12
5
F32.9
ICD-10 Finland
Depressive episode, unspecified
5.7
9.0
26
53
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
5.9
9.0
25
49
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
8.5
9.0
19
25
F00.10*G30.1
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
53.1
8.8
10
*
P99
ICPC
Psychological disorders other
29.4
8.6
11
*
RT150
NOMESCO Finland
NA
95.1
8.5
9
*
F06.4
ICD-10 Finland
Organic anxiety disorder
95.1
8.5
9
*
F0201, G310
ICD-10 Finland
NA
+∞
8.4
8
*
N05AD01
ATC
haloperidol; systemic
10.3
8.0
15
16
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
4.5
7.8
28
73
G31.8
ICD-10 Finland
Other specified degenerative diseases of nervous system
47.4
7.8
9
*
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
47.4
7.8
9
*
F05.9
ICD-10 Finland
Delirium, unspecified
10.9
7.7
14
14
N05AX12
ATC
aripiprazole; systemic
26.5
7.7
10
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
0.1
7.5
*
271
G30.8
ICD-10 Finland
Other Alzheimer disease
84.0
7.5
8
*
R41.3
ICD-10 Finland
Other amnesia
10.2
7.5
14
15
F064, G310
ICD-10 Finland
NA
+∞
7.3
7
*
G30.0
ICD-10 Finland
Alzheimer disease with early onset
+∞
7.3
7
*
F22.0
ICD-10 Finland
Delusional disorder
16.8
7.3
11
7
SPAT1234
SPAT
Support of social functional capacity
5.5
7.3
21
43
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
21.2
7.2
10
5
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
31.6
7.2
9
*
Z03.2
ICD-10 Finland
Observation for suspected mental and behavioural disorders
41.9
6.8
8
*
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
8.4
6.8
14
18
AA1AD
NOMESCO Finland
CT of head and brain
2.6
6.6
60
304
N06AB04
ATC
citalopram; systemic
3.0
6.6
42
171
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
72.7
6.5
7
*
SPAT1245
SPAT
Provision of support and information to patient’s family members
5.4
6.3
18
37
P72
ICPC
Schizophrenia
27.9
6.3
8
*
F060, G310
ICD-10 Finland
NA
+∞
6.3
6
*
G12.2
ICD-10 Finland
Motor neuron disease
+∞
6.3
6
*
N05AH02
ATC
clozapine; systemic
+∞
6.3
6
*
F020, G310
ICD-10 Finland
NA
+∞
6.3
6
*
F02.00
ICD-10 Finland
Dementia in Pick's disease without additional symptoms
+∞
6.3
6
*
N03AX09
ATC
lamotrigine; oral
8.2
6.3
13
17
R53
ICD-10 Finland
Malaise and fatigue
2.8
6.3
44
193
F29
ICD-10 Finland
Unspecified nonorganic psychosis
13.3
6.2
10
8
A04
ICPC
Weakness/tiredness general
3.3
6.2
33
119
P76
ICPC
Depressive disorder
10.7
6.1
11
11
SPAT1216
SPAT
Assessment of functional ability
2.8
6.0
43
190
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
29
11
31.23
42.69
1.0
1.0
838.2
552.8
ng/l
—
20
5
29
28
12.15
26.95
1.1
1.2
1.6
3.6
e6/l
1.67
21
22
28
28
11.66
25.37
1.1
1.4
125.5
111.0
e6/l
0.04
20
22
79
306
3.82
17.07
2.0
1.7
1287.6
1189.2
nmol/l
0.42
61
228
18
31
6.34
10.28
1.2
1.5
—
—
—
0
0
18
31
6.34
10.28
1.2
1.5
—
—
—
0
0
103
627
2.50
8.32
2.9
2.0
89.9
95.5
pmol/l
0.64
58
319
89
507
2.49
8.30
2.6
3.3
2.4
2.4
mmol/l
0.09
73
437
61
297
2.59
7.87
3.2
3.2
2.4
2.5
mmol/l
1.01
46
252
38
146
3.03
7.65
2.5
2.5
35.2
37.3
u/l
0.10
33
117
40
179
2.59
5.98
1.9
1.9
—
—
—
0
0
39
175
2.57
5.79
1.9
1.8
—
—
—
0
0
41
189
2.51
5.76
11.3
8.2
—
—
—
0
0
28
113
2.75
5.09
2.6
1.7
1.4
1.7
%
1.28
23
94
52
283
2.18
4.94
3.0
3.0
1.3
1.0
e6/l
0.30
24
165
101
702
2.00
4.92
7.4
5.7
1.2
1.2
mmol/l
0.11
89
632
64
380
2.06
4.84
1.8
1.6
20.4
20.5
nmol/l
0.02
58
316
13
35
3.93
4.45
1.1
1.1
—
—
—
0
0
48
263
2.13
4.44
2.9
3.2
7.2
2.9
e6/l
0.58
20
147
45
248
2.09
4.08
1.9
1.9
—
—
—
0
0
92
652
1.84
3.93
4.2
4.8
35.4
35.0
g/l
0.29
80
613
83
579
1.80
3.66
3.9
3.4
—
—
—
0
0
69
466
1.78
3.33
3.9
3.3
0.3
0.6
e6/l
1.08
52
348
16
60
2.83
3.33
2.1
2.9
4.0
4.3
pmol/l
—
10
55
70
476
1.77
3.29
2.6
2.0
433.2
249.8
u/l
0.56
62
443
101
769
1.71
3.13
7.7
6.6
1.2
1.2
mmol/l
0.51
82
644
42
270
1.72
2.32
3.0
3.2
0.8
0.8
mmol/l
0.07
35
251
55
381
1.64
2.30
2.8
2.1
3.3
3.2
mg/l
0.08
48
339
18
88
2.16
2.20
1.9
1.6
—
—
—
0
0
5
12
4.25
1.83
1.0
1.1
—
—
—
0
0
0
47
0.00
1.73
0.0
1.6
—
—
—
0
0
31
199
1.67
1.71
11.1
6.9
0.8
1.1
mmol/l
0.07
25
162
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
56
2.22
1.65
2.3
1.9
0.4
0.4
u/ml
—
7
26
118
1019
1.46
1.59
5.7
3.9
13.9
15.1
pmol/l
4.80
105
891
124
1376
0.68
1.52
3.9
5.0
1.4
1.5
mmol/l
1.29
106
1236
16
87
1.92
1.51
5.3
6.1
26.6
24.8
mmol/l
1.06
16
87
123
1359
0.70
1.37
6.1
6.7
40.3
41.1
mmol/mol
0.36
113
1253
12
61
2.04
1.36
2.4
2.2
42.1
36.8
g/l
—
6
52
0
38
0.00
1.36
0.0
1.3
—
—
—
0
0
127
1395
0.70
1.36
5.1
5.2
6.2
6.1
mmol/l
0.30
114
1256
131
1170
1.44
1.36
28.2
17.8
39.4
39.5
%
0.05
91
752
126
1384
0.70
1.32
4.0
5.0
4.6
4.5
mmol/l
0.20
107
1253
12
62
2.00
1.31
2.4
2.6
1.3
0.6
g/l
—
7
54
5
18
2.83
1.29
1.2
1.6
159.6
295.3
mu/l
—
5
18
25
164
1.61
1.29
3.2
2.4
8.8
9.1
ug/l
0.02
18
147
6
126
0.46
1.22
1.2
1.3
—
—
—
0
0
19
119
1.67
1.17
1.3
1.4
—
—
—
0
0
128
1154
1.38
1.14
7.3
8.0
83.0
80.3
u/l
0.23
112
1082
54
664
0.73
1.10
3.1
4.4
—
—
—
0
0
131
1416
0.73
1.08
4.7
5.7
2.7
2.6
mmol/l
0.24
114
1276
19
122
1.62
1.07
3.2
3.4
85.2
84.5
ng/l
0.02
13
109
123
1340
0.74
1.04
3.5
4.4
1.4
1.3
mmol/l
1.51
103
1197
0
30
0.00
0.98
0.0
1.1
—
23.1
—
0
25
39
299
1.39
0.97
4.1
3.7
62.1
135.4
ng/l
0.96
34
253
12
70
1.77
0.95
2.4
2.2
2.9
3.3
g/l
—
7
55
9
154
0.56
0.93
1.1
1.3
—
—
—
0
0
67
562
1.31
0.93
2.6
2.3
74.1
79.6
nmol/l
1.00
55
489
96
846
1.29
0.91
9.1
9.5
4.8
4.2
e9/l
1.05
79
733
12
72
1.71
0.87
2.4
2.0
8.4
10.2
g/l
—
6
63
92
812
1.27
0.84
5.8
3.5
63.5
57.2
u/l
0.15
84
739
23
165
1.45
0.83
2.0
3.5
7.9
9.3
umol/l
0.18
18
145
74
638
1.27
0.82
2.9
2.2
—
—
—
0
0
16
228
0.67
0.75
1.3
1.3
20.9
48.0
iu/ml
—
5
82
141
1488
0.76
0.75
24.8
20.2
76.5
82.6
umol/l
2.07
141
1488
137
1280
1.29
0.74
6.8
4.7
2.9
2.0
mu/l
0.68
118
1125
12
78
1.58
0.67
2.4
2.1
4.9
3.8
g/l
—
7
54
12
78
1.58
0.67
2.4
2.1
—
—
—
0
0
12
78
1.58
0.67
2.4
2.1
7.2
7.8
g/l
—
7
56
0
20
0.00
0.60
0.0
1.8
—
—
—
0
0
42
350
1.26
0.60
1.4
1.8
459.9
446.3
pmol/l
0.11
33
290
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
3.3
—
28.6
—
0
5
146
1387
1.28
0.60
21.8
16.5
31.9
25.5
mg/l
1.28
111
1123
62
541
1.22
0.59
2.9
2.7
90.4
158.6
ug/l
3.23
53
493
0
23
0.00
0.58
0.0
1.1
—
6.4
—
0
8
23
178
1.33
0.56
3.6
3.6
—
—
—
0
0
47
404
1.22
0.52
5.8
4.3
0.0
0.0
estimate
—
7
140
7
50
1.42
0.45
1.3
1.2
—
—
—
0
0
7
50
1.42
0.45
1.3
1.2
—
—
—
0
0
89
820
1.17
0.45
5.0
6.7
10.4
11.8
umol/l
0.85
80
781
16
205
0.76
0.43
1.5
1.3
1.9
15.5
u/ml
—
6
78
13
96
1.38
0.43
1.5
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
319.9
—
0
16
129
1348
0.85
0.41
20.8
15.9
76.3
73.6
ml/min/173m2
0.92
107
1100
0
17
0.00
0.41
0.0
1.1
—
7.1
—
0
11
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
70
637
1.16
0.40
4.1
4.2
28.0
45.1
ng/l
1.34
52
507
60
663
0.86
0.40
4.8
5.3
2.0
2.9
ug/l
0.68
50
586
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
36
415
0.83
0.40
2.3
3.1
355.7
7019.9
umol/l
1.73
24
339
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
39
340
1.19
0.38
2.2
2.5
—
—
—
0
0
29
249
1.20
0.33
1.4
2.2
2.3
2.3
g/l
0.03
21
229
31
270
1.18
0.31
1.5
2.2
11.3
13.2
umol/l
0.85
24
246
77
718
1.13
0.30
5.5
5.6
0.0
0.0
estimate
—
8
151
145
1488
0.87
0.26
12.5
11.7
24.1
24.8
u/l
0.24
135
1425
76
713
1.11
0.26
4.7
4.2
0.0
0.0
estimate
—
8
151
77
724
1.11
0.25
4.6
4.2
0.0
0.0
estimate
—
7
143
94
894
1.11
0.25
8.4
4.9
7.2
6.9
mmol/l
0.77
82
840
36
325
1.13
0.23
1.9
1.8
1.4
1.4
mg/l
0.03
26
262
52
560
0.90
0.22
5.4
4.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
14.8
—
0
12
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
5
43
1.17
0.21
1.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
15.2
—
0
13
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.26
0.20
1.0
1.4
—
—
—
0
0
7
61
1.15
0.18
1.9
1.3
—
—
—
0
0
118
1146
1.09
0.17
29.2
20.7
14.0
13.9
%
0.13
110
1124
151
1488
1.09
0.12
28.6
19.5
139.7
139.7
mmol/l
0.08
141
1450
150
1521
0.92
0.12
32.5
24.3
130.7
134.6
g/l
2.26
142
1494
5
47
1.07
0.09
1.0
1.6
—
—
—
0
0
151
1492
1.07
0.09
27.6
19.6
4.0
4.0
mmol/l
1.58
141
1457
8
75
1.07
0.07
4.9
2.4
1.3
1.1
%
—
8
75
12
109
1.11
0.06
35.9
6.6
25.4
24.6
mmol/l
0.42
12
104
55
561
0.97
0.03
2.7
3.2
708.5
1574.4
ng/l
2.93
49
483
48
472
1.02
0.01
2.9
2.5
45.2
58.4
u/l
2.87
42
434
38
387
0.98
0.01
2.4
3.2
0.9
0.8
ug/l
0.08
32
272
13
136
0.95
0.00
1.6
2.9
148.3
220.2
ng/l
0.50
13
119
105
1056
0.99
0.00
3.2
4.5
13.5
14.2
mm/h
0.20
94
959
54
538
1.01
0.00
3.8
4.7
22.6
22.1
%
0.09
20
283
27
275
0.98
0.00
1.4
1.2
0.6
1.5
u/ml
—
7
72
5
53
0.94
0.00
1.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
11.7
—
0
5
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
1.3
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.6
—
84.2
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
5.8
—
212.5
—
0
8
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
5
51
0.98
0.00
1.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
90.9
—
0
7
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint FTD and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| FTD | 3.562 [2.87, 4.42] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.253 |
During the follow-up period (1.1.1998 — 31.12.2019), 577 out of 1114 females with FTD died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| FTD | 4.074 [3.11, 5.33] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.017 |
During the follow-up period (1.1.1998 — 31.12.2019), 493 out of 822 males with FTD died.
Mortality risk
Mortality risk for people of age
years, who have FTD.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.343% | 0.872% |
| 5 | 2.068% | 5.012% |
| 10 | 5.094% | 12.523% |
| 15 | 9.351% | 21.829% |
| 20 | 15.906% | 34.13% |
Relationships between endpoints
↥Index endpoint: FTD – Frontotemporal dementia
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data